Securities Code: 688271 Securities abbreviation: United Imaging Medical Bulletin No.: 2023-001.

Shanghai United Shadow Medical Technology Co., Ltd.

Announcement on the progress of the implementation of some of the company's fund-raising projects.

the company's board of directors and all directors to ensure that the contents of this announcement does not exist any false records, misleading statements or major omissions, and the authenticity, accuracy and completeness of the contents of the individual and joint responsibility.

Important Content Tips:

After the completion of this fund-raising investment project will further support the company's future development of scale and

Globalization, expansion of the company's high-end medical imaging equipment production capacity, the current fund-raising projects continue to advance.

To help improve the level of the company's product investment in the diagnosis of the new crown epidemic and accelerate the company's product and technology upgrades,

Improve the level of localization of core components, expand the company's domestic and foreign market share, and promote the company to become one.

A world-class leader in medical innovation.

Basic situation of 1. fund-raising investment projects

According to the "Approval for Approval of the Registration of the Initial Public Offering of Shanghai United Imaging Medical Technology Co., Ltd." (Zheng Jian Ke [2022] No. 1327) issued by the China Securities Regulatory Commission, the company is allowed to publicly issue people to the public

Currency common stock (A shares) 100 million shares, the issue price is 109.88 yuan/share, the total amount of funds raised 1,098,800

Ten thousand yuan. The total amount of funds raised by the company after deducting all stock issuance expenses (including underwriting and sponsorship fees excluding VAT and other issuance expenses) of RMB 264,158,460.63, the net amount of funds raised is RMB 10,723,841,539.37. The above-mentioned fund-raising situation has been verified by PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership), and issued PricewaterhouseCoopers Zhongtian Inspection Word (2022) No. 0687 "Capital Inspection Report". For details, please refer to Shanghai United Imaging Medical Technology Co., Ltd. (hereinafter referred to as the "Company") disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on August 19, 2022.

The company held the 14th meeting of the first board of directors and the first board of supervisors on September 26, 2022

At the 12th meeting, the proposal on adjusting the amount of funds to be invested in the investment project of raised funds was deliberated and passed, and it was agreed that the company should raise the net amount of funds according to the actual amount of funds raised in the initial public offering of shares, combined with the actual amount of funds raised in the project

In the international situation, the amount of funds to be invested in the fund-raising project will be adjusted. According to the "Announcement of Shanghai United Imaging Medical Technology Co., Ltd. on Adjusting the Amount of Funds to be Invested in Raised Funds Investment Projects" (Announcement No. 2022-001), the fund-raising funds investment projects and the plan for the use of the fund-raising funds disclosed are as follows:

Unit: RMB ten thousand yuan

No. Project Name Total Investment Amount of Raised Funds Investment Amount

1. Next Generation Product Research and Development Project 616,792.14 466,235.09

2. Marketing Services Network Project 73,506.31 57,972.88

High-end Medical Imaging Equipment Industrialization Fund

3. Item 312,560.30 312,560.30

4. Information Promotion Project 45,158.91 35,615.88

5. Supplementary working capital 200,000.00 200,000.00

Total 1,248,017.66 1,072,384.15

Progress of 2. fund-raising investment projects

The "next generation product research and development project" in the company's fund-raising project is based on the existing core technologies and products, promoting the upgrading and research and development of each product line, the research and development of important core components, and the upgrading and optimization of the overall technology research and development platform. Up to now, the iterative upgrade of existing product technology and the development of new products and new technologies are progressing in an orderly manner according to the expected schedule, and the development of the overall technology research and development platform is promoted to match the product pipeline. With the gradual implementation of the above-mentioned projects, the company's second-generation products will be further improved in terms of parameter performance, core technology, platform, internationalization, etc., and the independent control ability of core technology will be further strengthened.

The "high-end medical imaging equipment industrialization fund project" in the company's investment projects specifically includes:(1) building a new high-end intelligent manufacturing factory, purchasing and installing necessary production line production equipment, automatic upgrading equipment, automatic control equipment, three-dimensional warehouse and logistics equipment, and building an intelligent system in the factory area. after completion, it is mainly used to produce high-end XR, CT, PET/CT, MR and PET/MR series of products;(2) New production research and development building;(3) New supporting complex building and other supporting facilities. At present, the first layer of earthwork excavation has been completed in the production R & D building, and the first support construction is in progress. The high-end intelligent manufacturing plant and comprehensive supporting building have also been officially started in early December 2022, and test pile construction is currently underway. The project will be used to produce high-end XR, CT,

PET/CT, MR and PET/MR series of products, of which XR and CT products can be used for the disease of the new crown epidemic.

Disease diagnosis, the construction of each project is in an orderly way.

The "informatization improvement project" in the company's fund-raising projects is a comprehensive upgrade of the company's informatization construction, which mainly includes IT infrastructure, information security, data governance center, sales operation system, production operation system, product research and development system and administrative management system. Up to now, the company has completed the first phase of the upgrade of sales and after-sales business opportunities and order management system, and the upgrade of other business systems such as production and operation system and product research and development system has been approved and is in different stages of implementation as planned. The phased progress of this project will help the company to improve internal management and operational efficiency in the process of business globalization, utilize and mine data value, and realize digital management.

The "supplementary working capital project" in the company's fund-raising projects further optimized the company's capital structure and met the company's demand for working capital for operation and development.

The Impact of 3. on Listed Companies and the Existing Risks

After the completion of the company's fund-raising investment project, it will further support the scale and globalization of the company's future development, and expand the company's high-end medical imaging equipment production capacity. Accelerate the company's product and technology upgrades, improve the localization level of core components, expand the company's domestic and foreign market share, and promote the company to become a world-class medical innovation leader. In view of the fact that the implementation of the fund-raising project still takes time, and it also takes a certain period to produce economic benefits, the emergence of the benefits of the use of raised funds requires a process, and there are certain risks such as market risks and operational risks after the completion of the project. please pay attention to the investment risk. The company will pay close attention to the follow-up progress of the project, timely discharge of information disclosure obligations.

It is hereby announced.

Shanghai United Shadow Medical Technology Co., Ltd. Board of Directors

January 3, 2023